Perrigo announced that it has received U.S.FDA approval for the generic version of Valeant Pharmaceutical International, Inc.'s BenzaClin® Pump Topical Gel. BenzaClin® Pump Topical Gel (clindamycin phosphate 1% and benzoyl peroxide 5%) is indicated for the topical treatment of acne vulgaris.
Combined generic and branded sales for the twelve months ending February 2016 were $79 million.
Perrigo's Chief Executive Officer John T. Hendrickson stated, "This Rx product approval and launch provide our customers with convenient, cost effective technologies like the BenzaClin® Pump."
